Navigation Links
Trazodone in Medical News

Labopharm to host webcast presentation on novel trazodone formulation - tomorrow (Dec.16/08) at 10:00 a.m. ET

LAVAL, QC, Dec. 15 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) will host a webcast presentation on, Tuesday, December 16, 2008, at 10:00 am (ET) during which the Company's senior management team will discuss the product profile, clinical and regulatory progress and the mark...

Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder

LAVAL, QC, Nov. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) today announced that it will host a webcast presentation on Tuesday, December 16, 2008 at 10:00 am (ET) during which the Company's senior management team will discuss the product profile, clinical and regulatory...

Labopharm's NDA for Novel Trazodone Formulation accepted for review by FDA

- Action Date is July 18, 2009 - LAVAL, QC, Nov. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) today announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SAR...

Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug

LAVAL, QC, Sept. 25 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has completed patient enrolment in its North American Phase III clinical trial for its once-daily formulation of the antidepressant trazodone (study 04ACL3-001). More than 400 patients ...

Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone

- Study Achieves Primary Efficacy Endpoint and Demonstrates Improved Quality of Sleep - LAVAL, QC, Feb. 8 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that its recently completed North American Phase III clinical trial for its onc...

Labopharm Reports Results for Second Quarter Fiscal 2009

...inue to prepare for commercialization of our novel trazodone formulation in the U.S.," concluded Mr. Howard-Tri..., the United Kingdom, Spain and Italy. Novel trazodone Formulation Company to Submit Response to FDA...e Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is...

Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference

... 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on...

Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)

... 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on...

Labopharm receives complete response letter from the U.S. FDA for novel antidepressant

... not been questioned about the continued supply of trazodone hydrochloride to the U.S. market. Angelini intends...arm submitted the NDA for its novel formulation of trazodone in September 2008. The NDA is based on data from f...e Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is...

Labopharm amends debt facility agreement with Hercules

...round the world, including the U.S., Canada, major European markets, and Australia, among others. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in...
Trazodone in Medical Technology

Labopharm files New Drug Submission with Health Canada for novel antidepressant

...sants represents a significant opportunity for our trazodone formulation and we are currently in discussions wi...score from baseline to the end of the study in the trazodone group versus the placebo group. Statistical signif...'s trazodone. In addition, patients on Labopharm's trazodone demonstrated significant improvements versus place...
Other Tags
(Date:4/18/2014)... discovery that turns 160 years of neuroanatomy on its ... to be essential for the fast transmission of impulses ... ubiquitous as thought, according to a new work lead ... Institute (HSCI) and the University,s Department of Stem Cell ... of Harvard,s Department of Molecular and Cellular Biology. , ...
(Date:4/18/2014)... 18, 2014) Benaroya Research Institute at Virginia Mason ... a particular molecule in metastatic breast cancer reduces both ... lung metastases. BRI scientists have found in models of ... by 60 - 80 percent and can keep the ... $1.8 million five-year grant comes from the National Cancer ...
(Date:4/18/2014)... is available in French . ... surgical practice and regenerative medicine. A team led by ... (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire ... has just demonstrated that the principle of adhesion by ... to repair soft-tissue organs and tissues. This easy-to-use gluing ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2
(Date:4/17/2014)... under clinical trials to treat tuberculosis could be the ... against various bacteria, fungal infections and parasites, yet evade ... chemists and collaborators. , Led by U. of I. ... ways the drug SQ109 attacks the tuberculosis bacterium, how ... from yeast to malaria and how targeting multiple ...
(Date:4/17/2014)... suggests that fish consumption advisories for expecting mothers ... contaminants like persistent organic pollutants (POPs). , ... including University of Toronto Scarborough PhD student Matt ... different levels of environmental contamination, a mother,s compliance ... the body influenced exposure in her children. , ...
(Date:4/17/2014)... A Kansas State University engineer has developed a ... detects improvised explosive devices. The same technique could ... the Steven M. and Kay L. Theede chair ... nuclear engineering, and his research team have created ... or in car trunks. The distance detection method ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2
Other Contents